Pulmonx Corporation — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; comparisons are with Q1 2023 unless otherwise stated. Pulmonx is a commercial-stage medical technology company focused on severe emphysema, primarily selling its Zephyr Endobronchial Valve alongside the Chartis assessment system and StratX lung-analysis platform.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 / prior period |
|---|---|---|
| Revenue | $18.9 million | $14.5 million; up 29.7% |
| Gross profit / margin | $14.1 million / 74.7% | $10.6 million / 72.9% |
| Operating expenses | $28.6 million | $27.0 million |
| Operating loss | $14.5 million | $16.4 million |
| Net loss / diluted loss per share | $13.7 million / $0.36 | $15.9 million / $0.42 |
| Cash used in operating activities | $11.8 million | $12.6 million |
| Cash, cash equivalents and marketable securities | $120.4 million | At March 31, 2024; cash and cash equivalents alone were $70.2 million |
| Debt, net of discount and issuance costs | $37.2 million | At March 31, 2024 |
Revenue growth reflected higher Zephyr Valve procedure volumes in the U.S. and international markets. U.S. revenue was $12.9 million, up from $9.3 million; international revenue was $6.0 million, up from $5.2 million. Gross margin improved 1.8 percentage points, which management attributed mainly to favorable geographic mix and higher manufacturing capacity utilization. SG&A rose 7.3% to $24.4 million, while R&D was nearly unchanged at $4.2 million. Higher interest expense partly offset improved operating results.
At March 31, 2024, total assets were $164.6 million, total liabilities $54.1 million, and stockholders’ equity $110.5 million. Current assets were $147.9 million and current liabilities $21.3 million. The company used $13.4 million of cash, cash equivalents and restricted cash during the quarter. Operating cash use included a $6.0 million decrease in accrued liabilities, primarily from payment of incentive compensation, and a $1.1 million inventory increase. The company held $19.8 million of inventory, including $2.5 million classified as long-term.
Material changes and notable items
- Net loss narrowed by $2.1 million year over year, while revenue grew 29.7% and gross margin expanded.
- SG&A increased by $1.7 million, including higher personnel-related costs and stock-based compensation. Stock-based compensation expense was $5.7 million, compared with $4.6 million a year earlier.
- The CIBC term loan carries a floating rate and had a 10.1% annual effective interest rate at quarter-end. Pulmonx reported compliance with all loan covenants. The debt is secured by substantially all company assets.
- In March, Pulmonx granted its new CEO inducement awards covering 630,402 shares. A modification of the former CEO’s unvested awards resulted in $6.3 million of total compensation expense to be recognized over remaining vesting periods; $0.3 million was recorded in Q1.
- Steven Williamson became President and CEO in March. Mehul Joshi was appointed CFO in April, after the quarter-end.
Outlook, risks and contingencies
Management expects continued net losses for several years and plans further investment in sales and marketing, R&D, clinical studies and product development. It believes existing cash, cash equivalents and marketable securities can fund planned operations for at least 12 months from issuance of the financial statements. Pulmonx expects longer-term needs to be met through available liquidity, product sales and potentially additional debt or equity financing; financing availability and terms are not assured. No specific revenue, earnings or margin guidance is provided in the filing.
- Regulatory investigation: The DOJ issued a civil investigative demand in December 2022 concerning relationships with certain healthcare providers, practices and hospitals in connection with Zephyr sales and marketing. Pulmonx is cooperating but cannot estimate the outcome or a reasonably possible loss; the matter could materially affect the business, results or financial condition.
- Commercial and reimbursement risk: Adoption depends on hospital, physician and patient uptake and adequate coverage. Medicare coverage is case-by-case, and some commercial insurers do not yet consider the procedure medically necessary.
- Product and clinical risk: The company cites risks including pneumothorax and other serious complications, and limited long-term safety and effectiveness data. Its business currently depends substantially on Zephyr Valve sales.
- Operational and financial risk: Pulmonx relies on single-source suppliers, manufactures at one primary facility, and faces competition, seasonality, foreign-exchange exposure and potential inflationary cost pressures. Its term loan includes minimum cash and revenue covenants.
- Leadership and controls: Management reported effective disclosure controls as of March 31, 2024 and no material change in internal control over financial reporting during the quarter.
Investor facts to verify
- Whether procedure growth and U.S. and international revenue trends continue, and how seasonality affects quarterly comparisons.
- Whether gross-margin gains persist as product mix, pricing, manufacturing costs and capacity utilization change.
- Cash-burn trajectory, liquidity runway, debt service and continued compliance with CIBC covenants.
- Developments in the DOJ investigation, including any potential financial exposure or operating consequences.
- Progress on reimbursement coverage, physician adoption, clinical follow-up and the CEO/CFO leadership transition.